about
Inhibitor of MYC identified in a Kröhnke pyridine libraryPhosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alphaPhosphatidylinositol 3-kinase: the oncoprotein.MYCNOS functions as an antisense RNA regulating MYCNOncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K)In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.The butterfly effect in cancer: a single base mutation can remodel the cell.MYC regulates the non-coding transcriptome.Essential role of Stat3 in PI3K-induced oncogenic transformationProteinInferencer: Confident protein identification and multiple experiment comparison for large scale proteomics projectsA Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block SignalingPI 3-kinase and cancer: changing accentsSingle-nucleotide polymorphism discovery by targeted DNA photocleavage.MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.PI3K and STAT3: a new alliance.[Ru(bpy)2(L)]Cl2: luminescent metal complexes that bind DNA base mismatches.Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator ComplexQuantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR.Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K).A butterfly effect in cancer.Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinaseDomain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.MINCR is not a MYC-induced lncRNA.A brave new MYC-amplified world.Stopping MYC in its tracks.Phosphorylation of AKT: a mutational analysis.Biochemical and biological characterization of tumor-associated mutations of p110alpha.Akt demoted in glioblastoma.tsRNA signatures in cancer.Synthetic molecules for disruption of the MYC protein-protein interfaceComprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMDAn MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferationPIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9Selenocysteine-Specific Mass Spectrometry Reveals Tissue-Distinct Selenoproteomes and Candidate SelenoproteinsIsoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets
P50
Q28656132-F7178FCC-79DE-4B27-8861-280BEE3425D2Q33823535-7E6DCE52-45E3-430F-B356-1F53C8ECE8ACQ34100548-2BFB5F62-C195-487F-BCF9-0FB86A8370C3Q34203861-65E48A39-420F-4682-A9C9-398ABFFB30A9Q34484148-3F22E850-AD6C-4B87-8039-70F632BFA714Q34601157-D13C79CD-B622-4234-9120-3800CEF1CADAQ34619131-8C722461-013E-4D7E-8933-88670FDCD980Q35037970-06FDA6B1-3243-4443-AD15-EB8A61FCDAD0Q35149681-50BC2959-8264-4FED-8FA9-3243E2183467Q35164627-8BCDC136-E40A-4CA6-A5F5-C928E14EE0DCQ36240436-5D9E500C-69D8-4A6D-AD68-0D3804539A16Q37222225-397B3DBC-1C46-4B2A-9069-D94396C0099BQ37351928-3A71C91A-D695-48F6-81D4-01A4330571D5Q37557403-4E396F5D-7641-4823-BCAA-FDD87DADB83FQ37715770-9A2F18D3-0ADD-496F-9280-8DAAAAA6EEA6Q37986079-CC29E49E-C1F0-4119-8E8E-777E4CC772D6Q38338799-6C0D7455-1949-49E9-98BC-7C2606C67BA1Q38818673-D6A660B3-43CB-459F-B6A6-267C68A2304AQ38852230-D741174D-F1D0-4470-9CC5-F7E28246BD92Q39586316-5DA9A74A-12D8-4761-95D7-EF37FB2DB67FQ40630278-99F24A0C-AA5B-4918-B296-3163F742849FQ40653471-EC17CFD9-0E01-49F4-BBDC-97558A824C94Q41348786-C7A202C2-0401-45A8-8891-8E4FDDC53C11Q42560918-9A1760DA-3AE0-4780-B73B-B705B84CD7BDQ42703324-3D5099F7-F035-49FB-8968-D806D6EEDD91Q42703346-ABDBCDD9-B661-4F3D-82E2-4F4689712A75Q42827667-DD20D8AC-8B01-4B70-85DD-71F760613689Q45961245-E9CAF983-243C-4A33-9EC1-796045E8A7A2Q46041818-67C53651-4B67-4122-B5C0-B7F89915F7F5Q50897488-AAFED21D-2A46-4548-AF76-8B22678F4A9FQ58170280-175D6BE6-FD5F-4BDB-8EBC-765C2CE677F8Q58767734-B3B8EA8E-39E6-4742-B23A-3ED9CAEDE60FQ90199025-7B7BB4CC-18ED-413C-9C02-E313D0E5910FQ90946541-0D527A8F-4927-4D89-BE54-3E7455C7AC77Q91264772-D835DC54-B86E-419E-80EA-0D87AA042FAEQ91389819-4E628C14-F5B1-4DA4-ABCC-7D149CD354F4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jonathan Ross Hart
@ast
Jonathan Ross Hart
@en
Jonathan Ross Hart
@es
Jonathan Ross Hart
@nl
Jonathan Ross Hart
@sl
type
label
Jonathan Ross Hart
@ast
Jonathan Ross Hart
@en
Jonathan Ross Hart
@es
Jonathan Ross Hart
@nl
Jonathan Ross Hart
@sl
altLabel
Jonathan R. Hart
@en
Jonathan Ross Hart
@en
prefLabel
Jonathan Ross Hart
@ast
Jonathan Ross Hart
@en
Jonathan Ross Hart
@es
Jonathan Ross Hart
@nl
Jonathan Ross Hart
@sl
P106
P108
P21
P31
P496
0000-0002-3905-225X